Heartseed, Inc. (JP:219A)
:219A
Want to see JP:219A full AI Analyst Report?
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥4,385.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥37.03B
Enterprise Value¥28.86B
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)36.5
Beta1.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage and a large equity base provide durable financial flexibility, lowering refinancing and solvency risk. This structural strength supports sustained R&D, clinical programs and partnership deals without immediate debt pressure, improving long-term operational optionality.
Positive Operating And Free Cash Flow In FY2025A shift to positive operating and free cash flow that closely tracked net income in FY2025 materially improves self-funding capacity. Durable cash generation, if sustained, reduces reliance on external financing and better funds clinical progression, partnerships, and commercialization investments.
Revenue Growth And Profitability TurnaroundA sharp revenue increase and healthy EBIT/net margins in FY2025 indicate the company can scale commercial or licensing activity while earning attractive margins. If persistent, this improves capital efficiency, supports reinvestment into pipelines, and validates the business model beyond the development phase.
Bears Say
Prior Multi-year Losses And Cash BurnA recent history of sustained losses and cash burn means the FY2025 improvement must be sustained to be deemed structural. Past funding dependence and execution shortfalls raise the risk that future clinical setbacks or slower commercialization could quickly reintroduce financing needs.
Inconsistent Gross Profit ReportingInconsistent gross profit metrics reduce confidence in margin comparability and obscure true product-level economics. This makes it harder to forecast sustainable margins, evaluate scalability of therapies, and assess whether reported profitability reflects core operations or one-time items.
Earnings And Cash-flow VolatilityPronounced earnings and cash-flow swings over recent years indicate execution and revenue-risk volatility. Such variability complicates long-term planning, may strain partner confidence, and increases the probability that a single clinical or commercial setback could erode recent financial gains.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥4385.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥37.03B.
When is Heartseed, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Heartseed, Inc.’s earnings last quarter?
Currently, no data Available
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,874,200 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Headquartered in Tokyo, Japan, Heartseed, Inc. was established on November 30, 2015, by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa, and Yutaro Kasai. The company specializes in the development and advancement of cardiac regenerative medicine.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―